Technical bottleneck of static molecular subtype classification and prognostic blind spot in HPV-negative head and neck squamous cell carcinoma (HNSCC) Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor with high molecular heterogeneity. Numerous subtype classification systems have been proposed in the field of genomic precision medicine. However, existing transcriptome-based molecular classifications remain at the level of describing the static genomic state of the tumor and do not translate into therapeutic decision-making for individual patients, creating a serious technical bottleneck. In particular, the HPV-negative (human papillomavirus-negative) HNSCC patient cohort, which is characterized by a high density of genetic mutations and frequent acquired drug resistance, has an extremely poor prognosis and lacks molecular-dynamic guidelines that could precisely match these tumors to targeted therapies—a critical blind spot.

Integration of multiple cohorts and CRISPR DepMap: identification of four tumor survival circuits To overcome the descriptive limitation of simple transcriptomic analysis and to compute drug-effective concentration thresholds mathematically, we aggregated multi-cohort RNA-seq metadata from five independent large-scale datasets, comprising a total of 727 tumors. The team combined this big data with genome-scale CRISPR dependency maps and a high-throughput pharmacologic screening pipeline using multidimensional tensor integration. After activating computational loops to filter noise, we discovered, for the first time, four core tumor survival circuits that physically drive the viability of HPV-negative HNSCC and their corresponding liability structures:

Machine-learning-derived 13-gene signature and ex vivo validation in 3D microtumors The molecular highlight of this study is the discovery that the epithelial-differentiated subtype among the four survival circuits is extremely sensitive to the targeted therapy EGFR inhibitor, and the translation of this dynamic correlation into a clinical screening engine. Using a machine-learning algorithm, we built a 13-gene signature model that predicts EGFR-inhibitor responsiveness from patient transcriptomic data. Prospective testing on a fresh patient-derived 3D microtumor platform demonstrated that the 13-gene signature score predicts actual tumor cell death in response to the EGFR inhibitor erlotinib with a remarkable correlation coefficient of R = 0.93, completely outperforming the conventional marker based solely on EGFR protein expression, which suffers from high false-positive rates.

Subtype-to-dependency-to-therapy framework and digital healthcare implementation The multi-omics systems-biology and CRISPR dependency data white paper delivers a disruptive impact on the global next-generation biopharma R&D and digital precision-diagnostic industry. It resets tumor diagnostics from static mutation annotation to a ‘transcriptomic state‑drug‑actionability linked real-time dynamic screening platform.’ By ingesting a patient’s RNA-seq data, the computational engine calculates weights for the four survival circuits and virtually recommends the optimal compound efficacy spectrum. This establishes a new standard for computer-based drug-selection engines, enabling multinational pharmaceutical companies to optimize precision stratification in pre-clinical stages of targeted-therapy development, maximize clinical success rates, and serve as a master reference that can dramatically shorten companion-diagnostic (CDx) regulatory approval timelines.